Safety and efficacy of intravitreal anti-VEGF injections for age-related macular degeneration

Current Opinion in Ophthalmology

Volumn 20, Issue 3, 2009, Pages 223-225

  Jeganathan, V E Swetha ^a,b   Verma, Nitin ^c,d  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b SINGAPORE EYE RESEARCH INSTITUTE   (Singapore)

^c ROYAL HOBART HOSPITAL   (Australia)

^d Hobart Eye Surgeons   (Australia)

Author keywords

Humans; Injections; Safety; Treatment outcome

Indexed keywords

BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; VASCULOTROPIN ANTIBODY; ANGIOGENESIS INHIBITOR; APTAMER; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

ANTIANGIOGENIC THERAPY; ARTERY THROMBOSIS; BLEEDING; CATARACT; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; CONJUNCTIVAL HEMORRHAGE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; ENDOPHTHALMITIS; EVIDENCE BASED PRACTICE; EYE DISCOMFORT; EYE DISEASE; EYE INFLAMMATION; EYE PROTECTION; HEART INFARCTION; HUMAN; HYPERTENSION; INJECTION SITE REACTION; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; OPTIC NERVE INJURY; PRIORITY JOURNAL; RECTUM CANCER; RETINA ARTERY OCCLUSION; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEOVASCULARIZATION; RETINA VEIN OCCLUSION; REVIEW; SIDE EFFECT; STROKE; SUBRETINAL NEOVASCULARIZATION; TRAUMATIC CATARACT; TREATMENT RESPONSE; DRUG ANTAGONISM; INJECTION; RETINA MACULA DEGENERATION; TREATMENT OUTCOME; VITREOUS BODY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; APTAMERS, NUCLEOTIDE; HUMANS; INJECTIONS; MACULAR DEGENERATION; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 65549113426     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICU.0b013e328329b656     Document Type: Review

References (22)

1. Klein R. Overview of progress in the epidemiology of age-related macular degeneration. Ophthalmic Epidemiol 2007; 14:184-187.
2. Seddon JM, Chen CA. The epidemiology of age-related macular degeneration. Int Ophthalmol Clin 2004; 44:17-39.
3. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age- related macular degeneration. N Engl J Med 2006; 355:1419-1431.
4. Ferris FL 3rd, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984; 102:1640- 1642.
5. Jonas JB. Intravitreal triamcinolone acetonide: a change in a paradigm. Ophthalmic Res 2006; 38:218-245.
6. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351:2805- 2816.
7. Donati G. Emerging therapies for neovascular age-related macular degeneration: state of the art. Ophthalmologica 2007; 221:366-377.
8. Chakravarthy U, Adamis AP, Cunningham ET Jr, et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age- related macular degeneration. Ophthalmology 2006; 113:1508.e1- 1508.e25.
9. Apte RS, Modi M, Masonson H, et al. Pegaptanib 1 -year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age- related macular degeneration. Ophthalmology 2007; 114:1702-1712.
10. Lanzl IM, Maier M, Feucht N, etal. Intraocular pressure effects of pegaptanib (macugen) injections in patients with and without glaucoma. Am J Ophthalmol 2008; 145:185; author reply 186.
11. Pegaptanib: new drug. In macular degeneration: too many risks for too little benefit. Prescrire Int 2006; 15:127-129.
12. Boyer DS, Antoszyk AN, Awh CC, et al. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007; 114:246-252.
13. Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham- controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008; 145:239-248.This phase lllb, multicenter, randomized-controlled trial evaluated the efficacy and safety of ranibizumab administered monthly for 3 months and then quarterly in patients with subfoveal CNV secondary to AMD.
14. Heier JS, Antoszyk AN, Pavan PR, et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase l/ll multicenter, controlled, multidose study. Ophthalmology 2006; 113:633.e1-633.e4.
15. Heier JS, Boyer DS, Ciulla TA, et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. Arch Ophthalmol 2006; 124:1532-1542.
16. Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005; 23:3697-3705.
17. Hurwitz H, Kabbinavar F. Bevacizumab combined with standard fluoropyr- imidine-based chemotherapy regimens to treat colorectal cancer. Oncology 2005; 69 (Suppl 3):17-24.
18. Lynch SS, Cheng CM. Bevacizumab for neovascular ocular diseases. Ann Pharmacother 2007; 41:614-625.
19. Weigert G, Michels S, Sacu S, et al. Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study. Br J Ophthalmol 2008; 92:356-360. This randomized control trial compared the functional and anatomical outcomes of intravitreal bevacizumab and verteporfin (photodynamic therapy) combined with intravitreal triamcinolone in patients with neovascular AMD.
20. Wu L, Martinez-Castellanos MA, Quiroz-Mercado H, et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin(R)): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 2008; 246:81 -87. This large study reported the cumulative systemic and ocular adverse events following intravitreal bevacizumab during 12 months of follow-up.
21. Ip MS, Scott IU, Brown GC, et al. Antivascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American Academy of Ophthalmology. Ophthalmology 2008; 115:1837- 1846.
22. This evidence-based review systemically reported the safety and efficacy of VEGF- A pharmacotherapies for the treatment of neovascular AMD.